Bayer faces an uphill fight with finerenone

Good, but perhaps not good enough. Such is the conclusion from the Fidelio-DKD trial of Bayer’s finerenone in diabetic kidney disease: the mineralocorticoid receptor antagonist hit its primary endpoint and demonstrated kidney-related and cardiovascular benefits – but the effect size lagged that seen with both Invokana and Farxiga.